| Document Date: 2014-02-06 00:38:22
Open Document File Size: 87,27 KBShare Result on Facebook
City WAYLAND / / Company Avaxia Biologics Inc. / / Country United States / / Currency USD / / Event FDA Phase / Funding / / Facility National Institute of Diabetes / / IndustryTerm treatment of celiac disease / platform technology / therapeutics for the treatment of gastrointestinal diseases / / MedicalCondition celiac disease / inflammatory bowel disease / disease / gastrointestinal disease / celiac sprue / oral mucositis / diabetes / systemic diseases / gluten-sensitive enteropathy / vomiting / pain / Celiac Disease WAYLAND / chronic diarrhea / obesity / autoimmune disease / acute radiation sickness / nontropical sprue / abdominal bloating / constipation / both diseases / gastrointestinal diseases / / MedicalTreatment radiation / / Organization National Institute of Health / National Institute of Diabetes and Digestive / Digestive and Kidney Diseases of the National Institutes of Health / / Person Barbara S. Fox / / Position CEO / / Product Develop Oral / / ProvinceOrState Massachusetts / / Technology radiation / antibodies / platform technology / / URL www.avaxiabiologics.com / /
SocialTag |
Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease WAYLAND, Mass. – March 10, 2011 – Avaxia Biologics, Inc., a privately-held biotech company using its proprietary pla